

Amendments to the Claims

Claim 1 (currently amended) A method of identifying compounds capable of inhibiting fibronectin-mediated processes, ~~comprising~~ comprising: determining whether a candidate compound selected from the group consisting of fragments of uteroglobin binds a fibronectin Type III polypeptide.

Claim 2 (original) The method of Claim 1 in which it is determined whether the compound binds the fibronectin Type III polypeptide in a competitive binding assay.

Claim 3 (original) The method of Claim 2 in which the fibronectin Type III polypeptide is an RGD-containing fibronectin Type III polypeptide.

Claim 4 (original) The method of Claim 2 in which the compound competes for binding with a uteroglobin-like compound.

Claim 5 (currently amended) The method of Claim 2 in which the compound competes for binding with uteroglobin ~~a 4-helix bundle polypeptide~~.

Claim 6 (canceled)

Claims 7 (original) The method of Claim 6 in which the uteroglobin is recombinant human uteroglobin.

Claim 8 (original) The method of Claim 1 in which the fibronectin-mediated process is cell adhesion.

Claim 9 (currently amended) A method of identifying compounds capable of inhibiting fibronectin-mediated processes, ~~comprising~~ comprising: determining whether a candidate

compound selected from the group consisting of fragments of uteroglobin inhibits or disrupts binding between a fibronectin Type III polypeptide and a uteroglobin-like compound.

Claim 10 (original) The method of Claim 9 in which the determination of whether a candidate compound inhibits or disrupts binding between a fibronectin Type III polypeptide and a uteroglobin-like compound is carried out in a competitive binding assay.

Claim 11 (original) The method of Claim 9 in which fibronectin Type III polypeptide is an RGD-containing fibronectin Type III polypeptide.

Claim 12 (original) The method of Claim 9 in which the uteroglobin-like compound is a 4-helix bundle polypeptide.

Claim 13 (original) The method of Claim 12 in which the 4-helix bundle polypeptide is uteroglobin.

Claim 14 (original) The method of Claim 13 in which the uteroglobin is recombinant human uteroglobin.

Claim 15 (original) The method of Claim 9 in which the fibronectin-mediated process is cell adhesion.

Claims 16-33 (canceled)

Claim 34 (currently amended) A method of identifying a compound capable of inhibiting a fibronectin-mediated process, comprising the steps of:

(a) contacting a candidate compound selected from the group consisting of fragments of uteroglobin of interest with a complex comprising a fibronectin Type III polypeptide and

a 4-helix bundle polypeptide uteroglobin; and

(b) determining whether the candidate compound competitively binds the fibronectin Type III polypeptide.

Claim 35 (currently amended) The method of Claim 34 in which the ~~4-helix bundle polypeptide~~ uteroglobin is labeled with a detectable label.

Claims 36-39 (canceled)

Claim 40 (new) A method for identifying compounds capable of at least one of fibronectin-dependent cell adhesion, polymerization, deposition or fibronectin-fibronectin interactions comprising the steps of:

(a) determining whether a candidate compound selected from the group consisting of fragments of uteroglobin inhibits a fibronectin mediated response, and

(b) determining whether a candidate compound selected from the group consisting of fragments of uteroglobin inhibits or disrupts binding between a fibronectin Type III polypeptide and a uteroglobin-like compound by determining whether said candidate compound inhibits cell adhesion, binds fibronectin or binds superfibronectin.

Claim 41 (new) The method of Claim 40 in which the determination of whether a candidate compound inhibits or disrupts binding between a fibronectin Type III polypeptide and a uteroglobin-like compound is carried out in a competitive binding assay.

Claim 42 (new) The method of Claim 40 in which the fibronectin type III polypeptide is an RGD-containing fibronectin Type III polypeptide.

Claim 43 (new) The method of Claim 40 in which the uteroglobin-like compound is a 4-helix bundle polypeptide.

Claim 44 (new) The method of Claim 43 in which the 4-helix bundle polypeptide is uteroglobin.

Claim 45 (new) The method of Claim 44 in which the uteroglobin is recombinant human uteroglobin.

Claim 46 (new) A method of identifying a compound capable of inhibiting of at least one of fibronectin-dependent cell adhesion, polymerization, deposition or fibronectin-fibronectin interactions comprising the steps of:

- (a) determining whether a candidate compound selected from the group consisting of fragments of uteroglobin inhibits a fibronectin mediated response,
- (b) contacting said candidate compound selected from the group consisting of fragments of uteroglobin with a complex comprising a fibronectin Type III polypeptide and a uteroglobin; and
- (c) determining whether said candidate compound selected from the group consisting of fragments of uteroglobin competitively binds the fibronectin Type III polypeptide by determining whether said candidate compound selected from the group consisting of fragments of uteroglobin inhibits cell adhesion, binds fibronectin or binds superfibronectin.

Claim 47 (new) The method of Claim 46 in which the uteroglobin is labeled with a detectable label.

Claim 48 (new) A method of identifying compounds capable of at least one of fibronectin-

dependent cell adhesion, polymerization, deposition or fibronectin-fibronectin interactions comprising the steps of:

- (a) determining whether a candidate compound selected from the group consisting of fragments of uteroglobin inhibits a fibronectin mediated response, and
- (b) determining whether a candidate compound selected from the group consisting of fragments of uteroglobin binds a fibronectin Type III polypeptide by determining whether said candidate compound selected from the group consisting of fragments of uteroglobin inhibits cell adhesion, binds fibronectin or binds superfibronectin..

Claim 49 (new) The method of Claim 48 in which it is determined whether the compound binds the fibronectin Type III polypeptide in a competitive binding assay.

Claim 50 (new) The method of Claim 49 in which the fibronectin Type III polypeptide is an RGD-containing fibronectin Type III polypeptide.

Claim 51 (new) The method of Claim 49 in which the compound competes for binding with a uteroglobin-like compound.

Claim 52 (new) The method of Claim 49 in which the compound competes for binding with uteroglobin.

Claims 53 (new) The method of Claim 52 in which the uteroglobin is recombinant human uteroglobin.

Claim 54 (new) The method of Claim 48 in which the fibronectin-mediated process is cell adhesion.